Zacks Small Cap Has Positive Estimate for ABEO Q3 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO) – Research analysts at Zacks Small Cap increased their Q3 2025 EPS estimates for Abeona Therapeutics in a note issued to investors on Wednesday, April 30th. Zacks Small Cap analyst D. Bautz now anticipates that the biopharmaceutical company will earn ($0.18) per share for the quarter, up from their prior forecast of ($0.34). The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.74) EPS, FY2026 earnings at $0.87 EPS and FY2027 earnings at $2.15 EPS.

Several other research analysts have also issued reports on ABEO. StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 24th. HC Wainwright raised their target price on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Oppenheimer started coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Abeona Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $18.75.

Abeona Therapeutics Price Performance

ABEO opened at $6.56 on Friday. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The company has a market cap of $320.13 million, a price-to-earnings ratio of -2.44 and a beta of 1.71. The stock has a fifty day simple moving average of $5.09 and a two-hundred day simple moving average of $5.62. Abeona Therapeutics has a 12-month low of $3.93 and a 12-month high of $7.32.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.19.

Insider Activity at Abeona Therapeutics

In other news, CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the sale, the chief executive officer now owns 1,355,322 shares in the company, valued at $6,478,439.16. This represents a 1.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 5.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Abeona Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Twinbeech Capital LP bought a new stake in shares of Abeona Therapeutics in the 4th quarter worth $58,000. Squarepoint Ops LLC bought a new stake in Abeona Therapeutics in the 4th quarter worth about $67,000. Cannon Global Investment Management LLC purchased a new position in Abeona Therapeutics in the 1st quarter worth about $67,000. Jane Street Group LLC purchased a new position in Abeona Therapeutics in the 3rd quarter worth about $84,000. Finally, Oxford Asset Management LLP bought a new position in Abeona Therapeutics during the 4th quarter valued at about $118,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.